Development of RA therapeutics binding to exosome derived from synovial cell

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K06936
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Biofunction/Bioprocess
• Research Institution: Hyogo University of Health Sciences
• Principal Investigator: Shibasaki Seiji 兵庫医療大学, 共通教育センター, 准教授 (50342530)
• Co-Investigator(Kenkyū-buntansha): 岩崎 剛 兵庫医療大学, 薬学部, 教授 (10151721)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 滑膜細胞 / エキソソーム

Outline of Final Research Achievements

To date, it has been thought that inflammatory cytokines and mediator molecules have important functions in T cell differentiation. It has been revealed that miRNAs, which are included in exosomes and secreted extracellularly, play an important role. In this study, we aimed to create an artificial ligand molecule capable of recognizing and binding to miRNAs and proteins contained in exosomes as the creation of a molecule that suppresses Treg differentiation, and worked on screening of an artificial ligand molecule. A plurality of artificial antibody clones having an antigen-binding ability were obtained by a method using a microtiter plate.

Free Research Field

生物工学

Academic Significance and Societal Importance of the Research Achievements

関節リウマチ（Rheumatoid arthritis:RA）は、正確な原因が不明な自己免疫疾患のひとつである。近年、抗体医薬の進歩に伴いRA患者の予後が改善されている。しかし、抗体医薬は、製造コストが薬価を高額にしており、感染症等の合併症で使用できないなど問題点がある。病原性T細胞分化に関わるmiRNAを含むエキソソームを阻害するタンパク質分子は、製造コストの優位性が考えられ、現在用いられているRA治療用抗体医薬の問題点を解決すると期待される。